umbrellalabs MK-2866 OSTARINE SARM 25MG/ML 30ML BOTTLE

Ostarine (Enobosarm) Overview Ostarine is an orally available, non-steroidal selective androgen receptor modulator (SARM) currently under investigation for several therapeutic applications. Research highlights its potential to support lean body mass, muscle strength, bone health, and metabolic balance, making it an alternative to traditional anabolic therapies with a more favorable safety profile. --- Clinical Trials and Findings Study 1 – Elderly Men & Postmenopausal Women A 12-week, randomized, double-blind, placebo-controlled Phase II trial evaluated Ostarine in 120 healthy elderly men and postmenopausal women. Doses ranged from 0.1 to 3.0 mg daily. Primary outcome: Ostarine significantly increased lean body mass in a dose-dependent manner, with the 3.0 mg group showing the largest improvement. Secondary outcomes: Enhanced stair climb power, modest reductions in fat mass (notably at 3.0 mg), and improved insulin sensitivity. No significant changes in body weight were noted. Safety: No androgenic side effects observed. Tolerability matched placebo, and adverse events were mild. Study 2 – Cancer Patients with Muscle Wasting A second Phase II trial (2007) evaluated Ostarine in men and women with cancer-related muscle wasting. Endpoints included lean mass, strength, and quality of life. Results: Both 1.0 mg and 3.0 mg doses significantly increased lean body mass and stair climb performance compared to placebo. Additional findings: No significant differences in hair growth (women) or PSA (men). Increases in liver enzyme ALT were transient and not treatment-limiting. Conclusion: Ostarine was well tolerated, with overall adverse event rates similar to placebo. Metabolic and Cardiovascular Safety Ostarine at 3.0 mg reduced fasting glucose and showed trends toward lower insulin, improving insulin resistance. Effects mirrored those of common antidiabetic drugs, suggesting potential in pre-diabetic and diabetic populations. Serum cholesterol, HDL, and triglycerides decreased, aligning with anabolic therapy’s known lipid effects. Cardiovascular safety appears favorable, especially compared to testosteron replacement therapy (TRT), which carries higher long-term risks. Hormonal Safety Reductions in SHBG (−61% men, −80% women) and total testosteron were observed, yet free testosteron levels remained stable. No clinical signs of androgenic imbalance were reported. These hormonal changes were expected and did not translate into adverse outcomes. --- Bone Health No significant change in bone mineral density during the 3-month trial, though preclinical studies show Ostarine has both anabolic and antiresorptive activity in bone. Longer studies are needed to clarify benefits for osteoporosis and bone strength. Functional Outcomes The stair climb test emerged as a reliable measure of functional improvement. Patients demonstrated faster climb times and increased power output, correlating with gains in lean body mass. Other functional endpoints (6-meter walk, hand grip strength) showed no significant differences, though stair climb results provide evidence for clinically meaningful functional benefit Overall Safety Profile Adverse events: Comparable to placebo across trials, mild in nature, and transient. Liver function: Temporary increases in ALT noted but without treatment discontinuation. Cardiovascular: Favorable safety-to-benefit ratio; no evidence of increased cardiovascular risk. Hormonal balance: Predictable SHBG and testosteron shifts without adverse androgenic outcomes. Long-term data: Needed to establish definitive safety in chronic use, especially regarding bone density and metabolic impacts. Key Clinical Takeaways Ostarine increases lean body mass and strength in elderly, postmenopausal, and cancer populations. Demonstrates significant improvements in stair climb performance, a functional measure tied to quality of life. Well tolerated with safety comparable to placebo in multiple Phase II trials. Improves insulin sensitivity and shows favorable metabolic effects. No androgenic side effects or concerning hormonal imbalances reported. Future studies are needed for long-term safety, bone health, and broader metabolic implications. Conclusion Ostarine (Enobosarm) is the most clinically advanced SARM, showing consistent benefits for muscle mass and function across diverse populations. Unlike TRT and anabolic steroids, it balances efficacy with a favorable safety profile, making it a strong candidate for treating muscle wasting, sarcopenia, and metabolic-related conditions. While additional long-term research is required, current evidence supports its promise as a safe and effective therapeutic option.